Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,827,168 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,827,168 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,825,740 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,825,740 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,849,737 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,849,737 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,859,453 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,859,453 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Talasaz and Eskandari 2017 Family Trust | 1,842,366 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,842,366 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 23,603 | $65.13 | $1,537,263.39 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 2 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,858,723 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 46,389 | $64.18 | $2,977,246.02 |
DisclosureSEC source: 0001628280-19-004662 · wf-form4_155614969045425.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 3,882,326 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.80 to $64.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The allocation of shares among such entities reported in the Reporting Person's Form 4 filed on October 11, 2018 was in error and has been corrected in this form. F3 · ownership.nature: The allocation of shares among such entities reported in the Reporting Person's Form 4 filed on October 11, 2018 was in error and has been corrected in this form. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionSERIES A PREFERRED STOCK · Derivative | 21,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012494 · wf-form4_153929371334478.xml · derivative · entry 6 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 0 Underlying: COMMON STOCK · 21,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Amended and Restated Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Amended and Restated Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Amended and Restated Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Amended and Restated Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 21,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012494 · wf-form4_153929371334478.xml · nonDerivative · entry 1 Talasaz AmirAli · CIK 0001753159 · Director · Chairman, President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Talasaz and Eskandari 2017 Family Trust Disclosed balance after: 4,153,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Amended and Restated Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.